Tango Therapeutics dropped about 5% today to US$26.34, yet the real story sits on the income statement. The company is still a development stage oncology player and the headline this half is the squeeze in profitability. Management reported a basic loss per share of US$0.69 for the first half of 2026 and a net loss of roughly US$100.9m, while revenue rounded to zero. For a stock that has swung sharply over the past month, the key question now is how long the balance sheet can keep funding this burn before the next capital decision arrives.

Is Tango Therapeutics a rare mispriced opportunity, or just another loss making biotech that looks cheap for a reason? Compare the stock's reported discount to fair value against our valuation analysis for Tango Therapeutics

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): US$0.0m vs. US$8.6m (revenue declined to zero as collaboration income rolled off)
• Net Loss (H1 2026 vs. H1 2025): US$100.9m loss vs. US$78.7m loss (loss widened)
• Basic EPS (H1 2026 vs. H1 2025): US$0.69 loss per share vs. US$0.71 loss per share (loss per share narrowed slightly)
• Pipeline Progress (Trailing 12 Months to H2 2025): 7 products in Phase I clinical development, highlighting Tango Therapeutics' early stage oncology portfolio

Prefer clean charts over scrolling through dense tables of trial costs and losses for Tango Therapeutics? See the company’s full financial picture, including a clear view of its balance sheet strength and cash runway, in our company report for Tango Therapeutics.

Tango Therapeutics: Bullish Story Meets Funding Reality

The bullish story around Tango Therapeutics centers on a broad precision oncology pipeline and strong pancreatic cancer data that supported a large equity raise of roughly US$566m to US$600m earlier in 2026. The latest half shows revenue at zero and a net loss of US$100.9m, yet the balance sheet now looks better able to carry that spend. Recent leadership hires focused on commercialization also fit a narrative of preparing for potential registration rather than winding back risk.

Losses, Volatility And The Bearish Read For Tango

On the bearish side, the new results underline how early Tango Therapeutics still is. There is no product revenue and losses have widened to US$100.9m in the half while the share price has slipped about 5% on the day and about 15% over 30 days. Revenue that previously came from collaborations has dropped to zero. That reinforces concerns that the story is now even more tied to successful development and future funding decisions, with little current income to offset a heavy R&D bill.

Compare the internal story Tango Therapeutics is telling with how the street is reacting. See the consensus price target analysis for Tango Therapeutics to find out whether analysts think the recent sell off lines up with their targets or creates a gap between price and expectations.

Stay Ahead With Tango Therapeutics

If the widening H1 2026 loss and zero revenue at Tango Therapeutics have your attention, register for free with Simply Wall St and add it to your Watchlist to track share price moves against fair value estimates and watch for a potential entry point. After you decide to build a position, use the Portfolio Command Center to cut through noise and focus on the most important developments that may affect your holdings. For a broader view on what other investors are thinking, turn to the Community and compare your thesis with a wide range of perspectives. That way you can surface hidden catalysts and risks early and stay a step ahead of the market.

Seeking Alternatives Beyond Tango Therapeutics

Fresh ideas move first. Stocks breaking out or quietly dropping can shift fast and leave latecomers caught off guard. Scan these curated picks before the crowd and review them promptly.

• Spot potential breakout compounders early and review the curated 20 high quality undiscovered gems while these stories are still under the radar for now and before momentum really builds.
• Lock onto resilient performers and scan the 85 resilient stocks with low risk scores to see which companies pair lower risk scores with steady footing while it still matters.
• Target cash generating opportunities and check the 8 dividend fortresses for income-oriented ideas that could help keep portfolios on a stable course if yields hold up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.